Ignite Creation Date:
2025-12-24 @ 4:34 PM
Ignite Modification Date:
2026-01-25 @ 8:55 PM
Study NCT ID:
NCT02194166
Status:
COMPLETED
Last Update Posted:
2019-06-10
First Post:
2014-07-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-07-18
Start Date Type:
ACTUAL
Primary Completion Date:
2018-07-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-07-12
Completion Date Type:
ACTUAL
First Submit Date:
2014-07-08
First Submit QC Date:
None
Study First Post Date:
2014-07-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-06-06
Last Update Post Date:
2019-06-10
Last Update Post Date Type:
ACTUAL